{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:44:26Z","timestamp":1774367066169,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,6]],"date-time":"2016-07-06T00:00:00Z","timestamp":1467763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.jns.2016.05.033","type":"journal-article","created":{"date-parts":[[2016,5,16]],"date-time":"2016-05-16T13:58:06Z","timestamp":1463407086000},"page":"56-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm"],"prefix":"10.1016","volume":"367","author":[{"given":"John","family":"Fezza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Truong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Hedges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2016.05.033_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.50.5_Suppl_5.S1","article-title":"Classification of dystonia","volume":"78","author":"Fahn","year":"1998","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.jns.2016.05.033_bb0010","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1600-0404.2004.00357.x","article-title":"Health-related quality of life in blepharospasm or hemifacial spasm","volume":"111","author":"Reimer","year":"2005","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jns.2016.05.033_bb0015","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/mds.25190","article-title":"Psychogenic facial movement disorders: clinical features and associated conditions","volume":"27","author":"Fasano","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2016.05.033_bb0020","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.clineuro.2008.09.023","article-title":"Quality of life in patients with focal dystonia","volume":"111","author":"Pekmezovic","year":"2009","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.jns.2016.05.033_bb0025","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/archopht.124.1.116","article-title":"Health-related quality of life and psychosocial characteristics of patients with benign essential blepharospasm","volume":"124","author":"Hall","year":"2006","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.jns.2016.05.033_bb0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/mds.1275","article-title":"Epidemiology of primary blepharospasm","volume":"17","author":"Defazio","year":"2002","journal-title":"Mov. Disord."},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2016.05.033_bb0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1468-1331.2010.03053.x","article-title":"The epidemiology of primary dystonia: current evidence and perspectives","volume":"17","author":"Defazio","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2016.05.033_bb0040","author":"Graham"},{"key":"10.1016\/j.jns.2016.05.033_bb0045","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-1331.2010.03042.x","article-title":"EFNS guidelines on diagnosis and treatment of primary dystonias","volume":"18","author":"Albanese","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2016.05.033_bb0050","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.toxicon.2012.12.004","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders","volume":"67","author":"Hallett","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.jns.2016.05.033_bb0055","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","article-title":"Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the therapeutics and technology assessment Subcommittee of the American Academy of neurology","volume":"70","author":"Simpson","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2016.05.033_bb0060","author":"Ipsen Biopharm, Ltd."},{"key":"10.1016\/j.jns.2016.05.033_bb0065","author":"Merz Pharma UK Ltd."},{"key":"10.1016\/j.jns.2016.05.033_bb0070","author":"Allergan"},{"key":"10.1016\/j.jns.2016.05.033_bb0075","author":"Allergan, Inc."},{"key":"10.1016\/j.jns.2016.05.033_bb0080","author":"Merz Pharmaceuticals L."},{"key":"10.1016\/j.jns.2016.05.033_bb0085","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/11584780-000000000-00000","article-title":"Content of botulinum neurotoxin in Botox\u00ae\/Vistabel\u00ae, Dysport\u00ae\/Azzalure\u00ae, and Xeomin\u00ae\/Bocouture\u00ae","volume":"10","author":"Frevert","year":"2010","journal-title":"Drugs R&D"},{"key":"10.1016\/j.jns.2016.05.033_bb0090","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1212\/WNL.37.4.616","article-title":"Botulinum a toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study","volume":"37","author":"Jankovic","year":"1987","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2016.05.033_bb0095","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/mds.23658","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm \u2013 a randomized trial","volume":"26","author":"Jankovic","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2016.05.033_bb0100","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00941758","article-title":"Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm","volume":"235","author":"Nussgens","year":"1997","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.jns.2016.05.033_bb0105","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","article-title":"NT 201 Blepharospasm Study Team. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm","volume":"113","author":"Roggenk\u00e4mper","year":"2006","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.jns.2016.05.033_bb0110","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/mds.870120627","article-title":"DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A\u2013Dysport and Botox\u2013assuming a ratio of 4:1","volume":"12","author":"Sampaio","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2016.05.033_bb0115","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.parkreldis.2007.11.003","article-title":"Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial","volume":"14","author":"Truong","year":"2008","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2016.05.033_bb0120","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00702-010-0529-x","article-title":"Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm","volume":"118","author":"Wabbels","year":"2011","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.jns.2016.05.033_bb0125","author":"Ipsen"},{"key":"10.1016\/j.jns.2016.05.033_bb0130","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00702-013-0998-9","article-title":"Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin\u00ae) injections in blepharospasm","volume":"120","author":"Truong","year":"2013","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.jns.2016.05.033_bb0135","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jns.2014.08.004","article-title":"IncobotulinumtoxinA (Xeomin\u00ae) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated","volume":"346","author":"Evidente","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2016.05.033_bb0140","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mds.22368","article-title":"Relationship between various clinical outcome assessments in patients with blepharospasm","volume":"24","author":"Jankovic","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2016.05.033_bb0145","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3111\/13696998.2011.653726","article-title":"Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia","volume":"15","author":"Sethi","year":"2012","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jns.2016.05.033_bb0150","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3111\/13696998.2014.925462","article-title":"Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians)","volume":"17","author":"Bensmail","year":"2014","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jns.2016.05.033_bb0155","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mds.870090216","article-title":"Development of resistance to botulinum toxin type A in patients with torticollis","volume":"9","author":"Greene","year":"1994","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2016.05.033_bb0160","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","article-title":"Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia","volume":"60","author":"Jankovic","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2016.05.033_bb0165","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","article-title":"U.S.XEOMIN cervical dystonia study group. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN\u00ae, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia","volume":"308","author":"Comella","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2016.05.033_bb0170","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00702-013-1048-3","article-title":"A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin\u00ae) in cervical dystonia","volume":"120","author":"Evidente","year":"2013","journal-title":"J. Neural Transm."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X16302921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X16302921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T20:56:59Z","timestamp":1536699419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X16302921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":34,"alternative-id":["S0022510X16302921"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2016.05.033","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2016.05.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}